Kevin L. Carter

Repeat Lipid Testing in Patients with Coronary Heart Disease
10/23/2013
Based on Adult Treatment Panel III guidelines, it is common current practice to suggest annual lipid testing in patients with coronary heart disease (CHD). Those with abnormal lipid levels are suggested to receive intensified treatment. For...
Based on Adult Treatment Panel III guidelines, it is common current practice to suggest annual lipid testing in patients with coronary heart disease (CHD). Those with abnormal lipid levels are suggested to receive intensified treatment. For...
Based on Adult Treatment Panel...
10/23/2013
First Report Managed Care
Management Strategies for Febuxostat as Chronic Therapy for Gout
05/24/2012
San Francisco—Gout affects as many as 5 million people in the United States and is the most common cause of inflammatory arthritis for men >40 years of age in the US. Traditionally, the goals of treatment for this condition have been to...
San Francisco—Gout affects as many as 5 million people in the United States and is the most common cause of inflammatory arthritis for men >40 years of age in the US. Traditionally, the goals of treatment for this condition have been to...
San Francisco—Gout affects as...
05/24/2012
First Report Managed Care
Older Patients with Mantle-Cell Lymphoma
12/17/2012
The long-term prognosis for older patients with mantle-cell lymphoma is poor. Only a minority of patients have a complete remission, and relapse or progression usually occurs within 2 to 3 years, resulting in an overall survival of <5...
The long-term prognosis for older patients with mantle-cell lymphoma is poor. Only a minority of patients have a complete remission, and relapse or progression usually occurs within 2 to 3 years, resulting in an overall survival of <5...
The long-term prognosis for...
12/17/2012
First Report Managed Care
Feature
Literature-Based Genetic Risk Scores and Cardiovascular Disease Events in Women
05/05/2010
Risk prevention in cardiovascular disease (CVD) has improved in recent years as genomewide association studies have found possible genetic and molecular markers (especially those in the 9p21 region) that are directly associated with CVD. But...
Risk prevention in cardiovascular disease (CVD) has improved in recent years as genomewide association studies have found possible genetic and molecular markers (especially those in the 9p21 region) that are directly associated with CVD. But...
Risk prevention in...
05/05/2010
First Report Managed Care
Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
08/16/2012
Thyroid cancer is the most common endocrine cancer, with >48,000 new cases occurring each year in the United States. Most cases are differentiated thyroid cancer, which is associated with a high 10-year survival rate of 90% to 95%. Many...
Thyroid cancer is the most common endocrine cancer, with >48,000 new cases occurring each year in the United States. Most cases are differentiated thyroid cancer, which is associated with a high 10-year survival rate of 90% to 95%. Many...
Thyroid cancer is the most...
08/16/2012
First Report Managed Care
Conference Insider
An Update on the Federal and State Legislative Picture
05/24/2012
San Francisco—“Of the many pieces of legislation and regulation being considered in Washington and on the state level, the Patient Protection and Affordable Care Act (ACA) is the most important,” said Thomas R. Bizzaro, RPh, vice president,...
San Francisco—“Of the many pieces of legislation and regulation being considered in Washington and on the state level, the Patient Protection and Affordable Care Act (ACA) is the most important,” said Thomas R. Bizzaro, RPh, vice president,...
San Francisco—“Of the many...
05/24/2012
First Report Managed Care
Nivolumab Plus Ipilimumab in Advanced Melanoma
10/23/2013
There has been increased interest in developing tumor immunity as a treatment strategy for several types of cancer. Immune checkpoint blockade is one approach that has induced regressions in cancer. Ipilimumab, a fully human, IgG1 monoclonal...
There has been increased interest in developing tumor immunity as a treatment strategy for several types of cancer. Immune checkpoint blockade is one approach that has induced regressions in cancer. Ipilimumab, a fully human, IgG1 monoclonal...
There has been increased...
10/23/2013
First Report Managed Care
News
New Onset Depression in Newly Diagnosed MS Patients
05/24/2012
San Francisco—Patients with multiple sclerosis (MS) are more likely to become depressed than healthy controls and patients with other chronic medical conditions. There are few data regarding the time to onset of depression in newly diagnosed...
San Francisco—Patients with multiple sclerosis (MS) are more likely to become depressed than healthy controls and patients with other chronic medical conditions. There are few data regarding the time to onset of depression in newly diagnosed...
San Francisco—Patients with...
05/24/2012
First Report Managed Care
Treatment of Benign Prostatic Hyperplasia
11/27/2012
Cincinnati—Benign prostatic hyperplasia (BPH) is the most common urological disorder in elderly men. There were an estimated 28.4 million patients with symptomatic BPH in the United States in 2010. As age increases, so does the prevalence of...
Cincinnati—Benign prostatic hyperplasia (BPH) is the most common urological disorder in elderly men. There were an estimated 28.4 million patients with symptomatic BPH in the United States in 2010. As age increases, so does the prevalence of...
Cincinnati—Benign prostatic...
11/27/2012
First Report Managed Care
Feature
A Phase 1-2 Trial of JAK1 and JAK2 Inhibitors in Myelofibrosis
01/04/2011
Myelofibrosis, a Philadelphia chromosomenegative myeloproliferative neoplasm, is characterized by progressive anemia, bone marrow fibrosis and splenomegaly, and produces debilitating symptoms. About 50% of patients with myelofibrosis carry a...
Myelofibrosis, a Philadelphia chromosomenegative myeloproliferative neoplasm, is characterized by progressive anemia, bone marrow fibrosis and splenomegaly, and produces debilitating symptoms. About 50% of patients with myelofibrosis carry a...
Myelofibrosis, a Philadelphia...
01/04/2011
First Report Managed Care

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use